FDA Accepts NDA For 177Lu-edotreotide for GEP-NETs – OncLive

… news release. ¹ “In the phase 3 COMPETE trial, ¹⁷⁷Lu-edotreotide demonstrated extended PFS, a straightforward dosing regimen, and a favorable …